Scalable Processing Options for Pharmaceutical Co-crystals

Time: 9:55 am - 10:15 am

Date: 1 May 2019

1-may-2019 09:55 1-may-2019 10:15 Europe/London Scalable Processing Options for Pharmaceutical Co-crystals

Active Pharmaceutical Ingredients (APIs) are primarily designed with therapeutic benefits in mind, such as on- and off- biotarget effects, as well as safety and toxicity criteria. Once a candidate API’s efficacy has been proven, downstream considerations such as bioavailability and physicochemical stability of formulations become more pressing. For challenging drug molecules, especially those with low… Read more »

Making Pharmaceuticals

Synopsis

Active Pharmaceutical Ingredients (APIs) are primarily designed with therapeutic benefits in mind, such as on- and off- biotarget effects, as well as safety and toxicity criteria. Once a candidate API’s efficacy has been proven, downstream considerations such as bioavailability and physicochemical stability of formulations become more pressing. For challenging drug molecules, especially those with low aqueous solubility, co-crystallisation offers an attractive path to modifying their physicochemical properties, without traditional synthetic modification of the API. This is achieved by introducing a second molecule into the crystal lattice during the crystallisation process. Ultimately, this can lead to significant performance improvements, for example better solubility, or notable inhibition of an undesirable feature, such as a needle-like crystal morphology. This discussion will focus broadly on pharmaceutical co-crystallisation, and its diverse areas of application. As the industry begins to adopt this approach more broadly, and indeed regulators begin to approve more co-crystal therapies, the need for scalable routes to co-crystal generation is front of mind. This presentation will explore if a single step, controlled crystallisation technology is an option to take this exciting area to the next level.

Speakers

« Back